BioMarin Pharmaceutical | BMRN - Interest Expense On Debt


BioMarin Pharmaceutical reported $14.96M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amgen USD 657M 4M Mar/2026
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Gilead Sciences USD 240M 15M Mar/2026
Incyte USD 569K 13K Mar/2026
Insmed USD 20.08M 517K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Moderna USD 11.49B 36B Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR -25M 99.78M Dec/2025
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
United Therapeutics USD 3.1M 100K Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025